CVnCoV Vaccine Uses, Dosage, Side Effects and more

The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

Trade Name CVnCoV Vaccine
Generic CVnCoV Vaccine
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share